Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results

Amylyx Pharmaceuticals reported third-quarter 2026 results and positive topline findings from its Phase 3 LUCIDITY trial of avexitide for post-bariatric hypoglycemia. The company said its New Drug Application submission remains on track for the end of 2026, and the trial results were accepted for a late-breaking oral presentation at ObesityWeek on November 15. An upsized public offering generated approximately $545 million in net proceeds, strengthening the company’s balance sheet.